© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer
Multiple Therapies Show Responses in Lung Cancer With ROS1 Fusions
August 03, 2020
Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib for lung cancer with ROS1 fusions and how to treat them.
Recommendations for Managing Patients With Lung Cancer During COVID-19 Era
July 31, 2020
In response to the COVID-19 pandemic, the European Society of Medical Oncology has published recommendations for the management of patients with lung cancer to maintain high-quality standards of treatment.
FDA Grants Breakthrough Therapy Designation to Osimertinib in EGFR+ Lung Cancer
July 30, 2020
The FDA granted Breakthrough Therapy designation to osimertinib as adjuvant treatment of patients with stage IB-IIIA EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.
Results of Pooled Analysis Show Positive Data for Trilaciclib in ES-SCLC
July 27, 2020
Jared Weiss, MD, discusses the pooled analysis of 3 phase 2 trials looking at trilaciclib in patients with extensive-stage small cell lung cancer.
Targeting KRAS-Mutant Tumors With Indirect Targeting of Related Pathways Yields Hope in Solid Tumors
July 25, 2020
The efficacy of each combination therapy targeting KRAS will likely depend on the tumor lineage, said Gordon Mills, MD, PhD.
Pembrolizumab Plus Chemotherapy Elicits Intriguing Responses in Nonsquamous NSCLC
July 21, 2020
In an interview with Targeted Oncology, Delvys Rodriguez-Abreu, MD, discussed the findings from the KEYNOTE-189, which established the combination of pembrolizumab plus pemetrexed and platinum chemotherapy as the new standard of care for patients with metastatic nonsquamous non-small cell lung cancer.
Researchers Release Alternative Treatment Strategies During COVID-19 for NSCLC
July 16, 2020
A nationwide group of clinical investigators teamed up to explore options on how to manage patients with locally advanced non-small cell lung cancer in a multidisciplinary setting during the ongoing pandemic of coronavirus disease 2019.
VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations
July 03, 2020
Xiuning Le, MD, PhD, discusses the results of tepotinib in patients with advanced non-small cell lung cancer and a MET exon 14 skipping mutation.
Positive Tepotinib Data Underscore Value of Liquid Biopsies in Non-Small Cell Lung Cancer
July 01, 2020
In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discussed the results of the phase II VISION study, which evaluated tepotinib in patients with advanced non-small cell lung cancer and harbor the MET exon 14 skipping mutation. She also highlighted the role of liquid biopsy in this space.
HITTING THE TARGET: Multigene Tests Gain Foothold in More Clinical Settings
June 29, 2020
Broad adoption of testing methods that allow for assessing all possible actionable targets and diagnostic markers in advanced cancer is becoming more complex with greater availability of lifesaving targeted therapies.